COVID-19 I IMUNOTERAPIJA U JUVENILNOM IDIOPATSKOM ARTRITISU
Sažetak
Pandemija COVID-19 predstavlja ogroman izazov za pedijatre širom sveta. Deca obolela od juvenilnog idiopatskog artritisa (JIA) koja imaju COVID-19 i koja su po indikacijama na biološkoj terapiji mogu predstavljati medicinsku i etičku dilemu. Nastojali smo da u ovom radu odgovorimo na pitanje da li je sklonost ka egzacerbacijama JIA nakon preležane infekcije COVID-19 veća kod dece sa JIA na biološkoj terapiji nego kod dece sa JIA koja nisu na biološkoj terapiji. Osim toga, ispitali smo motivaciju roditelja za vakcinaciju dece i simptome bolesti COVID-19 u ovoj populaciji. Retrospektivna studija sprovedena je na osnovu rezultata ankete rađene između 10. 3. 2022. i 12. 5. 2022. godine koja je obuhvatila 65 pedijatrijskih bolesnika i bolesnica. Anketa je sadržala niz zatvorenih i otvorenih pitanja na koja su odgovarali roditelji. Deo podataka koji se ticao trajanja JIA, brojeva telefona i terapije preuzet je iz Heliant informacionog sistema. Za poređenje grupa korišćen je Hi-kvadrat test. Pokazalo se da je najčešći simptom bila temperatura, a pratili su je simptomi vezani za gornji respiratorni trakt. Egzacerbacija osnovne bolesti koja je usledila nakon COVID-19 infekcije u grupi dece na biološkoj terapiji sa JIA potvrđena je u četiri slučaja, dok je u grupi dece sa JIA koja nisu bila na biološkoj terapiji pogoršanje zabeleženo dva puta. Prilikom poređenja dveju pomenutih grupa nije nađeno statistički značajno odstupanje. Motivacija roditelja za vakcinaciju protiv SARS-CoV-2 bila je izuzetno niska. Studija koja bi obuhvatila veći broj obolelih od JIA dala bi pouzdanije podatke o uticaju COVID-19 na ovu grupu bolesnika. Predlaže se formiranje jedinstvene baze podataka dece sa JIA, budući da bi ona u budućnosti mogla pomoći kliničarima da poboljšaju kvalitet života ovih bolesnika.
Reference
Alsohime F, Temsah MH, Al-Nemri AM, Somily AM, Al-Subaie S. COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome. J Infect Public Health 2020;13(12):1791-6. [CrossRef] [PubMed]
Barello S, Maiorino G, Palamenghi L, Torri C, Acamora M, Gagliardi L, et al. Exploring the Motivational Roots of Getting Vaccinated against COVID-19 in a Population of Vaccinated Pediatric Healthcare Professionals: Evidence from an Italian Cross-Sectional Study. Vaccines (Basel) 2022;10(3):467. [CrossRef] [PubMed]
Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J 2017;34(2):90-101. [CrossRef] [PubMed]
Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J Pediatr 2022;181(4):1597-607. [CrossRef] [PubMed]
Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2020;20(7):725-40. [CrossRef] [PubMed]
Elmas B, Çavdaroğlu PD, Orhan MF, et al. Evaluation of taste and smell disorders in pediatric COVID-19 Cases. Rev Assoc Med Bras (1992) 2021;67(6):789-94. [CrossRef] [PubMed]
Evans S, Klas A, Mikocka-Walus A, German B, Rogers GD, Ling M, et al. "Poison" or "protection"? A mixed methods exploration of Australian parents' COVID-19 vaccination intentions. J Psychosom Res 2021; 150:110626. [CrossRef] [PubMed]
Fernández-Sarmiento J, De Souza D, Jabornisky R, Gonzalez GA, Arias López MDP, Palacio G. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatr Open 2021;5(1): e000894. [CrossRef] [PubMed]
Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19(6):320-34. [CrossRef] [PubMed]
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19 [published correction appears in Nat Rev Microbiol 2022 Feb 23;:]. Nat Rev Microbiol 2021;19(3):141-54. [CrossRef] [PubMed]
Hügle B, Krumrey-Langkammerer M, Haas JP. Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication. Pediatr Rheumatol Online J 2021;19(1):163. [CrossRef] [PubMed]
Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022;23(1):3-20. [CrossRef] [PubMed]
Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol 2020; 85:104502. [CrossRef] [PubMed]
Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am 2018;65(4):691-709. [CrossRef] [PubMed]
Naddei R, Alfani R, Bove M, Discepolo V, Mozzillo F, Guarino A, et al. Increased relapse rate during COVID-19 lockdown in an Italian cohort of children with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2021; 75(2): 326-31. [CrossRef] [PubMed]
Naso J, Rojas S, Peng J, Marquez C, Conteras M, Castellanos E, R, et al. High Parental Vaccine Motivation at a Neighborhood-Based Vaccine and Testing Site Serving a Predominantly Latinx Community. Health Equity 2021;5(1):840-6. [CrossRef] [PubMed]
Pan F, Zhao H, Nicholas S, Maitland E, Liu R, Hou Q. Parents' Decisions to Vaccinate Children against COVID-19: A Scoping Review. Vaccines (Basel) 2021;9(12):1476. [CrossRef] [PubMed]
Paris C, Bénézit F, Geslin M, Polard E, Baldeyrou M, Turmel V, et al. COVID-19 vaccine hesitancy among healthcare workers. Infect Dis Now 2021;51(5):484-7. [CrossRef] [PubMed]
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377(9783):2138-49. [CrossRef] [PubMed]
Qi K, Zeng W, Ye M, Zheng L, Song C, Hu S, et al. Clinical, laboratory, and imaging features of pediatric COVID-19: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100(15):e25230. [CrossRef] [PubMed]
Salesi M, Shojaie B, Farajzadegan Z, Salesi N, Mohammadi E. TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control. Rheumatol Ther 2021;8(3): 1355-70. [CrossRef] [PubMed]
Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K, et al. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int 2021;41(4):751-762. [CrossRef] [PubMed]
Thunström L, Ashworth M, Finnoff D, Newbold SC. Hesitancy Toward a COVID-19 Vaccine. Ecohealth 2021;18(1):44-60. [CrossRef] [PubMed]
Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis Inflamm Bowel Dis 2021; 28(8): 1265-79. [CrossRef] [PubMed]
Verwoerd A, Ter Haar NM, de Roock S, Vastert SJ, Bogaert D. The human microbiome and juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016;14(1):55. [CrossRef] [PubMed]
Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J 2021;19(1):46. [CrossRef] [PubMed]
Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009;5(7):405-10. [CrossRef] [PubMed]
Wise J. Covid-19: Global death toll may be three times higher than official records, study suggests. BMJ 2022;376:o636. [CrossRef] [PubMed]
Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63(3):457-60. [CrossRef] [PubMed]
